Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Exagen Inc.NASDAQ: XGN

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $3.97M (cash outflow) rose 5.7% year over year, behind the +30.0% change in trailing-twelve-month net income. Sequentially, it fell 15.1% from the prior quarter. Over 3 fiscal years it compounded at -25.1% a year.

Context

  • Net income amounted to 30.0% of revenue in FY2025, up 2.8 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$15.58M (-21.9%) for the fiscal year ending Dec 2026, a slowdown from the +32.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.97M-15.1% QoQ
Last fiscal yearDec 2025
-$19.95M+32.0% YoY
LTMMar 2026
-$20.17M+30.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.7%+7.2%+1.4 pp
1 year+32.0%-21.9%-53.9 pp
3-year CAGR-25.1%-24.0%+1.0 pp
5-year CAGR-34.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(19.95M) USD
Year-over-year change
-32.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 net income of $20.17M is the 9th largest of the 11 companies compared; the peer median is $35.67M.
  • Its year-over-year change of +30.0% is the 3rd highest of 10, against a peer median of -24.6%.
  • Net income amounts to 29.5% of revenue for XGN, versus a peer median of 43.9%.
XGN Competitors Peer median
Net Income for XGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M +441.4%—110.0%
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M +26.6%+26.6%871.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M -46.5%-9.3%832.6%
NEONeoGenomics, Inc.LTM Jun 2026$51.88M -50.1%-9.2%6.8%
SGHTSight Sciences, Inc.LTM Mar 2026$37.25M -24.6%-23.6%46.8%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$34.09M —-30.8%25.2%
SMTISanara MedTech Inc.LTM Mar 2026$23.67M +103.8%+50.6%22.0%
STXSStereotaxis, Inc.LTM Mar 2026$21.68M -14.5%+5.8%69.5%
XGNExagen Inc.LTM Mar 2026$20.17M +30.0%-25.1%29.5%
TKNOAlpha Teknova, Inc.LTM Mar 2026$17.17M -26.3%-28.6%41.1%
MDXHMDxHealth S.A.FY2025$14.41M -41.7%-27.6%13.4%
Peer median (excluding XGN) $35.67M-24.6%-9.3%43.9%

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
Deferred Income Tax148K(306K)000
Stock-Based Compensation4.73M4.7M3.62M1.76M2.16M
Change in Working Capital(61K)1.67M325K(3.08M)(1.98M)
Accounts Receivables(744K)3.58M(474K)(1.28M)(3.02M)
Inventory00000
Accounts Payables(655K)901K67K308K42K
Other Working Capital1.34M(2.81M)732K(2.1M)997K
Other Non-Cash Items819K7.62M3.12M1.43M4.03M
Operating Cash Flow(20.27M)(32.14M)(14.46M)(13.28M)(13.63M)
Capital Expenditures(2.37M)(4.32M)(828K)(515K)(641K)
Acquisitions (Net)000015K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(50K)024K00
Investing Cash Flow(2.42M)(4.32M)(804K)(515K)(626K)
Debt Repayment(525K)(696K)(10.94M)(861K)2.01M
Common Stock Issued69.14M446K306K198K22.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.94M)(239K)000
Financing Cash Flow64.68M(489K)(10.63M)(663K)24.44M
Effect of Forex Changes00000
Net Change in Cash41.99M(36.95M)(25.9M)(14.46M)10.18M
Free Cash Flow(22.64M)(36.46M)(15.29M)(13.79M)(14.27M)

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.